Changes to agreements with Eli Lilly and Novartis’ sparked investor enthusiasm for the use of Jakafi in graft versus host disease.
Changes to agreements with Eli Lilly and Novartis’ sparked investor enthusiasm for the use of Jakafi in graft versus host disease.